Success for OPT 302 in the phase 3 trial would stand a better chance of " New Drug Application" when combined with a VEG A inhibitor in a single dose/injection and would be a true Blockbuster rendering all drugs that only target VEGF A obsolete. Then whole wet AMD market could be captive to a drug that combines the benefits of VEGF A,C and D inhibition in one dose. If combined wet AMD market for VEGF A inhibitors is $16BUS annual sales then a combination drug would be worth well north of $20BUS (this is speculation)but you get my drift!!
I note the volume traded in OPT today very low and finished wide. Still some cheap stock available in the low sixties!!
- Forums
- ASX - By Stock
- News: OPT Opthea Appoints Anshul Thakral As Non-Executive Director Of The Board
Success for OPT 302 in the phase 3 trial would stand a better...
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
63.0¢ |
Change
-0.010(1.56%) |
Mkt cap ! $775.5M |
Open | High | Low | Value | Volume |
64.0¢ | 64.5¢ | 62.8¢ | $1.826M | 2.864M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3870 | 63.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
64.0¢ | 259093 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 29393 | 0.625 |
2 | 76880 | 0.620 |
1 | 5000 | 0.615 |
2 | 44098 | 0.610 |
1 | 15752 | 0.605 |
Price($) | Vol. | No. |
---|---|---|
0.640 | 259093 | 5 |
0.645 | 26880 | 1 |
0.650 | 14500 | 3 |
0.655 | 16400 | 2 |
0.660 | 26448 | 2 |
Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |